The U.S. National Institute on Aging, one of the 27 institutes and centres that make up the NIH, is publicly advertising HIV and aging research funding opportunities through its extramural programme.

The notice, surfaced via NIA's public communications channel, directs investigators studying how chronic HIV infection interacts with age-related disease to the institute's grant mechanisms. NIA leads NIH's gerontology mission, supporting work on multimorbidity, cellular senescence, immunosenescence, and the long-term clinical sequelae of chronic viral infection. The institute typically prioritises projects that connect a defined aging biology endpoint to a measurable clinical or mechanistic outcome.

What does the announcement actually specify?

The source material available at the time of filing contains only the programme title and issuing institute. The underlying funding opportunity announcement — mechanism code, award ceiling, application deadline and named programme officer — did not come through in the input feed. Investigators should consult the NIH Guide to Grants and Contracts directly rather than rely on this dispatch.

Why HIV and aging now?

CDC surveillance puts the U.S. population living with HIV at roughly 1.2 million people, with more than half aged 50 or older. Antiretroviral therapy has converted HIV into a chronic condition for the treated majority, shifting the clinical burden toward cardiovascular disease, neurocognitive decline, frailty, osteopenia and other canonical hallmarks of aging.

Veterans Health Administration data show HIV-positive veterans aged 50+ now represent the majority of VA's HIV-positive caseload, a structural shift that has reshaped clinical workload in infectious disease and geriatrics clinics alike.

That demographic shift creates the portfolio question NIA is signalling it wants answered: how does chronic HIV infection, and its treatment, accelerate or reshape aging biology? Work on comorbidity clusters, immune ageing, mitochondrial dysfunction, and HIV-associated neurocognitive disorder has historically drawn NIA co-funding alongside the NIH Office of AIDS Research. Several prior NIA-supported studies have linked persistent immune activation to accelerated epigenetic age in treated cohorts.

What should labs and grants offices do next?

NIA routes HIV-and-aging applications through the standard NIH activity codes:

• The R01 research project grant funds longer, mechanistic programmes.
• The R21 exploratory/developmental grant supports shorter, higher-risk pilots.
• The R03 small research grant covers focused projects with modest budgets.

Specific caps sit per mechanism and per funding opportunity; PIs must read the full announcement to recover them.

The submission package follows standard NIH form: a research strategy structured around significance, innovation and approach; biosketches in the post-2021 format; and a data management and sharing plan compliant with the 2023 DMSP policy. Applications route to study sections administered by the Center for Scientific Review, not by NIA itself. Recent HIV-and-aging applications have been reviewed in the AIDS and Related Research Integrated Review Group (AARR) and in special emphasis panels convened by CSR.

For multi-PI or consortium submissions, PIs should budget additional lead time for the multiple-PI leadership plan and for subaward budgeting. International collaborators are permissible but require a separate justification in the resources section. Letters of support from clinical sites that can deliver aged HIV-positive cohorts carry weight in study section review, given the demographic specificity of the question.

What's missing from this dispatch

Because the source feed captured only the programme title and the issuing institute, no submission deadline, total funds available, named programme officer or quoted statement could be verified. Grants offices should pull the full opportunity from the NIH Guide before committing submission timelines.

NIA programme staff who previously shepherded HIV-and-aging portfolios have included project officers in the Division of Aging Biology and the Division of Geriatrics and Clinical Gerontology. Whether the current notice carries a specific contact stays unclear without the full text.

Forward outlook

NIA's continued advertising of HIV-and-aging funding signals an expectation that the research base on long-term HIV survivorship will grow through this decade, driven by the ageing of the U.S. HIV-positive cohort and the institute's parallel interest in inflammaging, geroscience and multimorbidity. The agency's geroscience initiative, which already intersects with HIV portfolios, positions NIA to absorb more applications linking viral reservoirs, chronic immune activation and age-related functional loss.